PELP1/MNAR suppression inhibits proliferation and metastasis of endometrial carcinoma cells

Wan,Jing; Li,Xiaomao

doi:10.3892/or.2012.2038

PELP1/MNAR suppression inhibits proliferation and metastasis of endometrial carcinoma cells

Authors:
- Jing Wan
- Xiaomao Li
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, The Third Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510630, P.R. China
Published online on: September 17, 2012 https://doi.org/10.3892/or.2012.2038
Pages: 2035-2042

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Proline-, glutamic acid- and leucine-rich protein-1/modulator of non-genomic activity of estrogen receptor (ER) (PELP1/MNAR) is a novel nuclear receptor (NR) co-activator that plays an essential role in the actions of ER. Emerging findings suggest that PELP1/MNAR is a novel proto-oncogene, whose expression is deregulated in several hormone-responsive cancers, including endometrial cancer. In this study, we demonstrate that PELP1/MNAR is widely expressed in endometrial carcinoma cell lines. To investigate its possible role in endometrial carcinoma progression, we adopted an RNA interference technology to downregulate PELP1/MNAR expression in Ishikawa endometrial carcinoma cells. PELP1/MNAR downregulation substantially reduced cell proliferation, and the cells in which PELP1/MNAR expression was knocked down also exhibited a decreased migration and invasion ability, as shown by Boyden chamber and invasion assays. The results showed that the expression of MMP-2 and MMP-9 was also decreased. These results suggest that PELP1/MNAR plays a role in endometrial cancer progression and metastasis, and that PELP1/MNAR may be a potential therapeutic target for endometrial cancer.

View Figures

View References

1	Whitcomb BP: Gynecologic malignancies. Surg Clin North Am. 88:301–317. vi2008. View Article : Google Scholar : PubMed/NCBI
2	Zhang H: Endocrine-related cancer. Encyclopedia of Cancer. Schwab M: 2nd edition. Springer-Verlag; Heidelberg: pp. 435–439. 2008
3	Shang Y: Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer. 6:360–368. 2006. View Article : Google Scholar : PubMed/NCBI
4	Pietras RJ, Levin ER and Szego CM: Estrogen receptors and cell signaling. Science. 310:51–53. 2005. View Article : Google Scholar : PubMed/NCBI
5	Shao W and Brown M: Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 6:39–52. 2004. View Article : Google Scholar : PubMed/NCBI
6	O'Lone R, Frith MC, Karlsson EK and Hansen U: Genomic targets of nuclear estrogen receptors. Mol Endocrinol. 18:1859–1875. 2004. View Article : Google Scholar
7	Bjornstrom L and Sjoberg M: Mechanisms of estrogen receptor signaling: convergence of genomic and non-genomic actions on target genes. Mol Endocrinol. 19:833–842. 2005. View Article : Google Scholar : PubMed/NCBI
8	Song RX, Zhang Z and Santen RJ: Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends Endocrinol Metab. 16:347–353. 2005. View Article : Google Scholar : PubMed/NCBI
9	Losel R and Wehling M: Non-genomic actions of steroid hormones. Nat Rev Mol Cell Biol. 4:46–56. 2004. View Article : Google Scholar
10	Mckenna NJ, Lanz RB and O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev. 20:321–344. 1999.PubMed/NCBI
11	Hall JM and Mcdonnell DP: Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting. Mol Interv. 5:343–357. 2005. View Article : Google Scholar : PubMed/NCBI
12	Barnes CJ, Vadlamudi RK and Kumar R: Novel estrogen receptor coregulators and signaling molecules in human diseases. Cell Mol Life Sci. 61:281–291. 2004. View Article : Google Scholar : PubMed/NCBI
13	Han SJ, Demayo FJ, Xu J, Tsai SY, Tsai MJ and O'Malley BW: Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor. Mol Endocrinol. 20:45–55. 2006. View Article : Google Scholar : PubMed/NCBI
14	O'Malley BW: Coregulators: from whence came these ‘master genes’. Mol Endocrinol. 21:1009–1013. 2007.PubMed/NCBI
15	Sakaguchi H, Fujimto J and Sun WS: Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers. J Steroid Biochem Mol Biol. 104:237–240. 2007. View Article : Google Scholar : PubMed/NCBI
16	Lanard DM, Lanz RB and O'Malhy BW: Nuclear receptor coregulators and human disease. Endocr Rev. 28:575–587. 2007. View Article : Google Scholar : PubMed/NCBI
17	Gururaj AE, Singh RR and Rayala SK: MTA1, a transcriptional activator of breast cancer amplified sequence 3. Proc Natl Acad Sci USA. 103:6670–6675. 2006. View Article : Google Scholar : PubMed/NCBI
18	Webb P, Valentine C and Nguyen P: ER beta binds N-CoR in the presence of estrogens via an LXXLL-like motif in the N-CoR C-terminus. Nucl Recept. 1:42003. View Article : Google Scholar : PubMed/NCBI
19	Mishra SK, Balasenthil S and Ngnyen D: Cloning and functional characterization of PELP1/MNAR promoter. Gene. 330:115–122. 2004. View Article : Google Scholar : PubMed/NCBI
20	Nair SS, Nair BC, Cortez V, Chakravarty D, Metzger E, Schüle R, Brann DW, Tekmal RR and Vadlamudi RK: PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep. 11:438–444. 2010. View Article : Google Scholar : PubMed/NCBI
21	Cheskis BJ, Greger J, Cooch N, et al: MNAR plays an important role in ERα activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids. 73:901–905. 2008.
22	Rajhans R and Vadlamudi RK: Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis. 23:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
23	Vadlamudi RK and Kumar R: Functional and biological properties of the nuclear receptor coregulator PELP1/MNAR. Nucl Recept Signal. 5:e0042007.PubMed/NCBI
24	Nair SS, Guo Z, Mueller JM, et al: PELP1/MNAR enhances androgen receptor functions through LIM-only coactivator FHL2. Mol Endocrinol. 21:613–624. 2007.PubMed/NCBI
25	Rajhans R, Nair S, Holden AH, Kumar R, Tekmal RR and Vadlamudi RK: Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res. 67:5505–5512. 2007. View Article : Google Scholar : PubMed/NCBI
26	Habashy HO, Powe DG, Rakha EA, et al: The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype. Breast Cancer Res Treat. 120:603–612. 2010. View Article : Google Scholar : PubMed/NCBI
27	Vadlamudi RK, Balasenthil S, Broaddus RR, Gustafsson JA and Kumar R: Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. Clin Endocrinol Metab. 89:6130–6138. 2004. View Article : Google Scholar : PubMed/NCBI
28	Dimple C, Nair SS, Rajhans R, et al: Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res. 68:4902–4909. 2008. View Article : Google Scholar : PubMed/NCBI
29	O'Malley BW and Kumar R: Nuclear receptor coregulators in cancer biology. Cancer Res. 69:8217–8222. 2009. View Article : Google Scholar
30	Chakravarty D, Tekmal RR and Vadlamudi RK: PELP1: a novel therapeutic target for hormonal cancers. IUBMB Life. 62:163–169. 2010.
31	Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, Raj GV, Tekmal RR, Sun L and Vadlamudi RK: Significance of PELP1 in ER-negative breast cancer metastasis. Mol Cancer Res. 10:25–33. 2012. View Article : Google Scholar : PubMed/NCBI
32	Balasenthil S and Vadlamudi RK: Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem. 278:22119–22127. 2003. View Article : Google Scholar : PubMed/NCBI
33	Nair BC, Nair SS, Chakravarty D, et al: Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res. 70:7166–7175. 2010. View Article : Google Scholar : PubMed/NCBI
34	Chakravarty D, Roy SS, Babu CR, Dandamudi R, Curiel TJ, Vivas-Mejia P, Lopez-Berestein G, Sood AK and Vadlamudi RK: Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 17:2250–2259. 2011. View Article : Google Scholar : PubMed/NCBI
35	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI